A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma (BREAKPOINT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03463681 |
Recruitment Status :
Completed
First Posted : March 13, 2018
Last Update Posted : April 26, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Metastatic Renal Cell Carcinoma | Drug: Cabometyx | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 49 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Open Label Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma Pretreated With One immunochecKPOint INhibiTor (Anti PD1/PDL1): the BREAKPOINT Trial |
Actual Study Start Date : | June 11, 2018 |
Actual Primary Completion Date : | April 8, 2021 |
Actual Study Completion Date : | April 8, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Cabozantinib
all subjects will recieve open label Cabozantinib 60 mg orally once daily
|
Drug: Cabometyx
cabozantinib 60 mg orally once daily
Other Name: cabozantinib |
- progression free survival (PFS) [ Time Frame: 28 month ]To assess the progression free survival (PFS) of cabozantinib in patients pretreated with one immunocheckpoint inhibitor (CPI) in monotherapy or in combination
- overall survival (OS) [ Time Frame: 28 month ]To assess the overall survival (OS)
- objective response rates (ORR) [ Time Frame: 28 month ]the efficacy based on objective response rates (ORR) according to RECIST 1:1 criteria
- safety: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 28 month ]Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed written informed consent
- One previous anticancer treatment with a PD1/PDL1 inhibitor, as monotherapy or in combination with an angiogenesis inhibitor or anti CTLA 4, in both setting first line or adjuvant ( in this case patient having recurrence during the adjuvant treatment or within 6 months after therapy with PD1-PD-L1 therapy)
- Age ≥18 years
- Patients with histological diagnosis of predominant clear cells renal cell carcinoma
- Measurable disease (as per RECIST 1.1 criteria) with documented radiological progression
- Fertile women (<2 years after last menstruation) and men of childbearing potential must use effective methods of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilisation) during the study and for 4 months after the last dose of study treatment
- All sites of disease including brain metastases (non symptomatic)
- Karnofsky performance status ≥ 70%
- Life expectancy greater than 3 months
-
The required values at baseline are as follows:
- Absolute neutrophil count >1.5 x 109 /L,
- Platelet count > 100 x 109 /L,
- Haemoglobin > 9g/dl,
- Total bilirubin < 1.5 upper limit of normal (ULN);
- AST, ALT<2.5 ULN in patients without liver metastases, <5 ULN in patients with liver metastases;
- serum creatinine < 2.0 mg/dl, amylase and lipase <1.5 ULN 11- Female subjects of childbearing potential must not be pregnant at screening
Exclusion Criteria:
- Major surgical procedure within 28 days prior to study treatment start
- Other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix, meningiomas)
- Clinically significant cardiovascular disease, for example cerebrovascular accidents (<6 months), myocardial infarction (<6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication
- Recent (within the 30 days prior to randomisation) treatment with another investigational drug or participation in another investigational study
- Symptomatic brain metastasis
- History of other disease, metabolic dysfunction, physical examination finding or clinical laboratory finding giving reasonable suspicion of a disease condition that contraindicates use of an investigational drug or patient at high risk from treatment complications
- PT or INR and PTT >1.5 times the Upper Normal Limit of the institution (patient who are being therapeutically anticoagulated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists).For patients on warfarin, close monitoring of at least weekly evaluations will be performed, until INR is stable based on a measurement at pre-dose, as defined by the local standard of care
- Previous or concomitant radiotherapy in the lesion parameter of disease
- Previous radiotherapy or other locoregional antitumoral treatment performed within 21 days before the study recruitment
- Uncontrolled hypertension (>= 160 mmHg systolic and/or 90 mmHg diastolic) while receiving chronic medication
- Inability to swallow tablets or capsules
- Female subject who is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women
- Known history of human immunodeficiency virus (HIV) infection, active hepatitis B, or active hepatitis C.
- Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03463681
Italy | |
Fondazione IRCCS Istituto Nazionale Tumori | |
Milan, Italy, 20133 |
Principal Investigator: | Giuseppe Procopio, MD | Fondazione IRCCS ISTITUTO NAZIONALE TUMORI |
Other Publications:
Responsible Party: | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
ClinicalTrials.gov Identifier: | NCT03463681 |
Other Study ID Numbers: |
2018-000582-36 |
First Posted: | March 13, 2018 Key Record Dates |
Last Update Posted: | April 26, 2021 |
Last Verified: | April 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Carcinoma Carcinoma, Renal Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms Urologic Neoplasms |
Urogenital Neoplasms Neoplasms by Site Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Kidney Diseases Urologic Diseases Male Urogenital Diseases |